On June 11, Akeso (09926.HK) declined 3.24% in regular trading, trading at HK$85.6/share, with trading volume of HK$93.45 million. The stock is now approaching its 52-week low of HK$82.15, with cumulative losses exceeding 30% from its post-ASCO high on June 1.

The decline continues the sustained sell-off following the ASCO Annual Meeting, where the company's core product Ivonescimab (AK112) demonstrated statistically significant OS benefit in the HARMONi-6 study (HR=0.66, P=0.0017) for first-line squamous NSCLC. Despite this landmark clinical achievement, event-driven funds have persistently taken profits since the data release. Additional headwinds include reports of potential US restrictions on investment in China's biotech sector, weighing on short-term sentiment.

Multiple institutions including CITICS, Zhongtai Securities, and Guotai Haitong maintain buy ratings with target prices significantly above current levels, yet selling pressure continues to dominate price action.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)